These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

550 related items for PubMed ID: 32139332

  • 1. Expression Profiling of Driver Genes in Female Never-smokers With Non-adenocarcinoma Non-small-cell Lung Cancer in China.
    Zhao Y, Dong Y, Zhao R, Zhang B, Wang S, Zhang L, Hu M, He Q, Zhang W, Han B.
    Clin Lung Cancer; 2020 Sep; 21(5):e355-e362. PubMed ID: 32139332
    [Abstract] [Full Text] [Related]

  • 2. Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests.
    Byeon S, Lee B, Park WY, Choi YL, Jung HA, Sun JM, Ahn JS, Ahn MJ, Park K, Lee SH.
    Clin Lung Cancer; 2020 May; 21(3):e182-e190. PubMed ID: 31839532
    [Abstract] [Full Text] [Related]

  • 3. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
    Tan AC, Lai GGY, Tan GS, Poon SY, Doble B, Lim TH, Aung ZW, Takano A, Tan WL, Ang MK, Tan BS, Devanand A, Too CW, Gogna A, Ong BH, Koh TPT, Kanesvaran R, Ng QS, Jain A, Rajasekaran T, Lim AST, Lim WT, Toh CK, Tan EH, Lim TKH, Tan DSW.
    Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042
    [Abstract] [Full Text] [Related]

  • 4. The Landscape of Actionable Molecular Alterations in Immunomarker-Defined Large-Cell Carcinoma of the Lung.
    Chan AW, Chau SL, Tong JH, Chow C, Kwan JSH, Chung LY, Lung RW, Tong CY, Tin EK, Law PP, Law WT, Ng CSH, Wan IYP, Mok TSK, To KF.
    J Thorac Oncol; 2019 Jul; 14(7):1213-1222. PubMed ID: 30978501
    [Abstract] [Full Text] [Related]

  • 5. Comprehensive molecular analysis of driver mutations in non-small cell lung carcinomas and its correlation with PD-L1 expression, An Indian perspective.
    Aggarwal A, Sharma S, Brar Z, Kumar V, Kumar A, Katara R, Mohanty SK.
    Pathol Res Pract; 2024 Jan; 253():155013. PubMed ID: 38096714
    [Abstract] [Full Text] [Related]

  • 6. Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations: Results from the IFCT Study Biomarkers France.
    Guibert N, Barlesi F, Descourt R, Léna H, Besse B, Beau-Faller M, Mosser J, Pichon E, Merlio JP, Ouafik L, Guichard F, Mastroianni B, Moreau L, Wdowik A, Sabourin JC, Lemoine A, Missy P, Langlais A, Moro-Sibilot D, Mazières J.
    J Thorac Oncol; 2017 Jun; 12(6):963-973. PubMed ID: 28189832
    [Abstract] [Full Text] [Related]

  • 7. Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.
    Wen S, Dai L, Wang L, Wang W, Wu D, Wang K, He Z, Wang A, Chen H, Zhang P, Dong X, Dong YA, Wang K, Yao M, Wang M.
    Oncologist; 2019 Nov; 24(11):e1070-e1081. PubMed ID: 30902917
    [Abstract] [Full Text] [Related]

  • 8. Genetic Profiling of Non-Small Cell Lung Cancer in Moroccan Patients by Targeted Next-Generation Sequencing.
    El Zaitouni S, Laraqui A, Ghaouti M, Benzekri A, Kettani F, Boustany Y, Benmokhtar S, Lamrani Alaoui H, El Annaz H, Abi R, Tagajdid MR, El Kochri S, El Mchichi B, Bouaiti EA, Lahlou IA, El Hassani RA, Ennibi K.
    Technol Cancer Res Treat; 2024 Nov; 23():15330338241288907. PubMed ID: 39363851
    [Abstract] [Full Text] [Related]

  • 9. Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative.
    Lim SM, Kim EY, Kim HR, Ali SM, Greenbowe JR, Shim HS, Chang H, Lim S, Paik S, Cho BC.
    Oncotarget; 2016 Apr 26; 7(17):24172-8. PubMed ID: 26992220
    [Abstract] [Full Text] [Related]

  • 10. Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the French cooperative thoracic intergroup (IFCT) biomarkers France project.
    Beau-Faller M, Pencreach E, Leduc C, Blons H, Merlio JP, Bringuier PP, de Fraipont F, Escande F, Lemoine A, Ouafik L, Denis M, Hofman P, Lacave R, Melaabi S, Langlais A, Missy P, Morin F, Moro-Sibilot D, Barlesi F, Cadranel J, French Cooperative Thoracic Intergroup (IFCT).
    Lung Cancer; 2020 Feb 26; 140():19-26. PubMed ID: 31841714
    [Abstract] [Full Text] [Related]

  • 11. Prospective genetic profiling of squamous cell lung cancer and adenosquamous carcinoma in Japanese patients by multitarget assays.
    Kenmotsu H, Serizawa M, Koh Y, Isaka M, Takahashi T, Taira T, Ono A, Maniwa T, Takahashi S, Mori K, Endo M, Abe M, Hayashi I, Nakajima T, Ohde Y, Yamamoto N.
    BMC Cancer; 2014 Oct 28; 14():786. PubMed ID: 25348872
    [Abstract] [Full Text] [Related]

  • 12. Abnormalities of epidermal growth factor receptor in lung squamous-cell carcinomas, adenosquamous carcinomas, and large-cell carcinomas: tyrosine kinase domain mutations are not rare in tumors with an adenocarcinoma component.
    Ohtsuka K, Ohnishi H, Fujiwara M, Kishino T, Matsushima S, Furuyashiki G, Takei H, Koshiishi Y, Goya T, Watanabe T.
    Cancer; 2007 Feb 15; 109(4):741-50. PubMed ID: 17238183
    [Abstract] [Full Text] [Related]

  • 13. Long-term clinical benefit from salvage EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer patients with EGFR wild-type tumors.
    Koinis F, Voutsina A, Kalikaki A, Koutsopoulos A, Lagoudaki E, Tsakalaki E, Dermitzaki EK, Kontopodis E, Pallis AG, Georgoulias V, Kotsakis A.
    Clin Transl Oncol; 2018 Feb 15; 20(2):140-149. PubMed ID: 28631135
    [Abstract] [Full Text] [Related]

  • 14. Assessment of cytology based molecular analysis to guide targeted therapy in advanced non-small-cell lung cancer.
    Li W, Zhang Z, Guo L, Qiu T, Ling Y, Cao J, Guo H, Zhao H, Li L, Ying J.
    Oncotarget; 2016 Feb 16; 7(7):8332-40. PubMed ID: 26789109
    [Abstract] [Full Text] [Related]

  • 15. [Precision medical treatment of non-adenocarcinoma NSCLC patients with EGFR mutation].
    Wang ZH, Song XY.
    Zhonghua Zhong Liu Za Zhi; 2017 Feb 23; 39(2):90-93. PubMed ID: 28219201
    [Abstract] [Full Text] [Related]

  • 16. Comprehensive analysis of oncogenic mutations in lung squamous cell carcinoma with minor glandular component.
    Pan Y, Wang R, Ye T, Li C, Hu H, Yu Y, Zhang Y, Wang L, Luo X, Li H, Li Y, Shen L, Sun Y, Chen H.
    Chest; 2014 Mar 01; 145(3):473-479. PubMed ID: 24158231
    [Abstract] [Full Text] [Related]

  • 17. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.
    Kim HR, Shim HS, Chung JH, Lee YJ, Hong YK, Rha SY, Kim SH, Ha SJ, Kim SK, Chung KY, Soo R, Kim JH, Cho BC.
    Cancer; 2012 Feb 01; 118(3):729-39. PubMed ID: 21720997
    [Abstract] [Full Text] [Related]

  • 18. The introduction of systematic genomic testing for patients with non-small-cell lung cancer.
    Cardarella S, Ortiz TM, Joshi VA, Butaney M, Jackman DM, Kwiatkowski DJ, Yeap BY, Jänne PA, Lindeman NI, Johnson BE.
    J Thorac Oncol; 2012 Dec 01; 7(12):1767-1774. PubMed ID: 23154547
    [Abstract] [Full Text] [Related]

  • 19. Mutational landscape and characteristics of ERBB2 in non-small cell lung cancer.
    Wei XW, Gao X, Zhang XC, Yang JJ, Chen ZH, Wu YL, Zhou Q.
    Thorac Cancer; 2020 Jun 01; 11(6):1512-1521. PubMed ID: 32291971
    [Abstract] [Full Text] [Related]

  • 20. Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials.
    Suh JH, Johnson A, Albacker L, Wang K, Chmielecki J, Frampton G, Gay L, Elvin JA, Vergilio JA, Ali S, Miller VA, Stephens PJ, Ross JS.
    Oncologist; 2016 Jun 01; 21(6):684-91. PubMed ID: 27151654
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.